Related by context. All words. (Click for frequent words.) 83 p = #.# [002] 80 p = #.# [004] 77 % CI #.#-#.# [002] 77 P = .# 75 confidence interval CI 72 n = 71 placebo p = 71 r = 71 CI = 69 % CI #.#-#.# [006] 68 CI -#.# 68 placebo p 67 P ≤ 66 p = .# [002] 66 statistically significant p 65 % CI #.#-#.# [007] 65 confidence interval #.#-#.# 65 % CI #.#-#.# [003] 65 sd = 65 placebo 65 % CI #.#-#.# [008] 64 CI #.#-#.# [002] 63 -#.# ± [002] 63 univariate analysis 62 % Confidence Interval 62 ≥ 62 statistically significant p = 62 df = 62 % CI #.#-#.# [001] 62 nonsignificant 62 ± SD 61 p = NS 61 nonfatal MI 61 p = #.# [003] 61 interquartile range 61 ± 61 Secondary endpoints included 61 creatinine ratio 60 β = 60 MADRS score 60 posttreatment 60 statistically significant 60 lopinavir r arm 60 log# copies mL 60 median PFS 60 LVEF 59 g dL 59 mmol L 59 achieved statistical significance 59 HbA 1c levels 59 MACCE 59 μmol L 59 p = .# [001] 59 p ≤ 59 lispro 59 IPSS 59 Hazard Ratio HR 59 highest tertile 59 pg mL 59 copies mL 59 DAS# [002] 59 CI #.#-#.# [001] 58 postintervention 58 progression TTP 58 TAXUS p value 58 pg ml 58 -#.# mg dL [002] 58 HbA1c levels 58 ß = 57 log# IU mL 57 oxycodone CR 57 CI #.#-#.# p = 57 -#.# p = 57 WOMAC pain 57 kappa = 57 preoperative 57 nonsignificant difference 57 Hazard Ratio = 57 MMSE score 57 mcg QD 57 lumbar spine BMD 57 Secondary endpoints 57 reach statistical significance 57 mg kg 57 postoperatively 57 Secondary endpoints include 57 r2 = 57 intima media thickness 57 ‰ ¥ 57 log# 57 postop 57 mcg kg 57 statistically significant improvement 57 reinfarction 57 composite endpoint 56 x ULN 56 confidence intervals CIs 56 % CI #.#-#.# [004] 56 AOR = 56 ipsilateral stroke 56 biochemical relapse 56 tirofiban 56 lowest tertile 56 secondary endpoint 56 nonobese 56 baseline HbA1c 56 IU mL 56 HBeAg negative patients 56 methotrexate monotherapy 56 tertile 56 laboratory abnormalities 56 Rating Scale MADRS 56 endometrial thickness 56 biochemical recurrence 56 statistical significance p 56 ng mL 56 hip BMD 56 tertiles 56 binary restenosis 56 statistically significant differences 56 -#.# mg dL [001] 56 QTcF 56 Median PFS 56 TEAEs 56 nondiabetic patients 56 #mg/day [001] 56 periprocedural 56 mcg BID 56 mm Hg 56 mg QD 55 Kaplan Meier analysis 55 PaO 2 55 CR nPR 55 FOLFIRI alone 55 stent binary restenosis 55 nmol liter 55 mg d 55 primary endpoint 55 leukopenia 55 diameter stenosis 55 HAQ DI 55 plus MTX 55 copies ml 55 NIHSS 55 AUC0 55 SGRQ 55 ug dose 55 statistically significant reduction 55 mg dL 55 mmol l 55 = #.#-#.# 55 infliximab monotherapy 55 femoral neck 55 multivariate adjustment 55 ng dL 55 #.#-#.# p = 55 5-FU/LV 55 aOR 55 pmol L 55 #.#/#.# mmHg [001] 55 DAS# remission 55 normotensive 55 placebo fluoxetine 55 PANSS scores 55 univariate 55 mmHg diastolic 55 = -#.# 55 #mg BID [001] 55 receiving ISENTRESS 54 Index CDAI 54 HBV DNA 54 mL/min/#.# m 2 54 4mg/kg 54 HbA 1c 54 severe hypoglycemic 54 demonstrated statistically significant 54 #mg QD [001] 54 alanine aminotransferase 54 mg kg dose 54 certolizumab 54 diastolic BP 54 comorbidity 54 univariate analyzes 54 Baseline characteristics 54 nonfatal myocardial infarction 54 ADAS cog 54 left ventricular systolic 54 discontinuations due 54 cerebrovascular events 54 Visual Analogue Scale VAS 54 IQR 54 febrile neutropenia 54 target vessel revascularization 54 ng ml 54 morphometric vertebral fractures 54 subscales 54 HF hospitalization 54 nasopharyngitis 54 HIV RNA 54 mRS 54 hypoglycemic events 54 unfractionated heparin 54 IIIa inhibitors 54 CDAI 54 mmHg p = 54 â ‰ ¥ 54 GERD symptom 54 HBeAg seroconversion 54 ropivacaine 54 pCR 54 virologic failure 54 mg p = 54 HOMA IR 54 definite stent thrombosis 54 atazanavir ritonavir 54 MADRS 54 severe neutropenia 54 chlorambucil 54 achieved ACR# 54 Hazard Ratio 54 annualized relapse 54 HbA1C levels 54 timepoints 54 #mg BID [003] 54 HbA1c 54 subscale scores 54 contralateral 54 nonresponders 54 Median progression 54 lopinavir r 54 comorbidities 54 XIENCE V vs. 53 serum concentrations 53 #mg QD [002] 53 CFQ R 53 liver histology 53 REYATAZ r arm 53 preoperatively 53 MMSE scores 53 tipranavir r 53 adjunctive placebo 53 nonfatal stroke 53 multivariable analysis 53 recurrent venous thromboembolism 53 mg BID 53 abdominal pain abdominal discomfort 53 plus medroxyprogesterone acetate 53 International Prostate Symptom 53 multivariate analysis 53 peginterferon alfa 2b 53 mIU L 53 plus methotrexate 53 g dl 53 WOMAC scores 53 μg mL 53 comparator arm 53 mg ustekinumab 53 NNT = 53 BMI z 53 atheroma volume 53 preintervention 53 RLAI 53 postoperative 53 PANSS 53 preoperative PSA 53 Expanded Disability Status 53 abacavir lamivudine 53 virologic response 53 evaluable 53 MetS 53 Crohn Disease Activity 53 LV ejection fraction 53 clinically meaningful improvement 53 comorbid 53 posttransplant 53 T2 lesion volume 53 QRS duration 53 nausea photophobia 53 elevated transaminases 53 Xalatan R 53 Brief Psychiatric 53 multivariable adjusted 53 tolterodine ER 53 bivalirudin monotherapy 53 femoral neck BMD 53 pT3 53 LPV r 53 ANOVA 53 mitoxantrone 53 subscore 53 extrapyramidal symptoms 53 Montgomery Asberg Depression 53 serum HCV RNA 53 Operative mortality 53 sumatriptan naproxen sodium 53 Lucentis monotherapy 53 prespecified 53 events MACE 53 mg kg Hematide 53 systolic BP 52 colorectal adenoma 52 DAS# scores 52 CCyR 52 NIH CPSI 52 myocardial infarction MI 52 XIENCE V PROMUS Stent 52 recurrent ischemia 52 free survival PFS 52 covariates 52 HCV RNA 52 -#.# log# copies mL 52 μg kg 52 multivariate Cox 52 Viread Emtriva Sustiva 52 EDSS scores 52 umol L 52 CABG 52 incontinence episodes 52 dyspnea 52 ABC/3TC 52 LAB GHRH 52 hematologic toxicity 52 secondary endpoints 52 receiving VICTRELIS 52 timepoint 52 #.#/#.# mm Hg [001] 52 nadroparin 52 Postoperative 52 refractory ischemia 52 nmol L 52 tHcy 52 tamsulosin 52 vertebral fracture 52 experienced virologic failure 52 mg TID 52 intact parathyroid hormone 52 % CI #.#-#.# [005] 52 Primary endpoints 52 log# reduction 52 #mg/day [002] 52 EQ 5D 52 μg 52 quetiapine 52 paresthesias 52 CR CRu 52 distant metastasis 52 dapagliflozin plus 52 advanced adenoma 52 PSQI 52 postoperative complication 52 ATV RTV 52 -#.# log# 52 prior relapsers 52 ejection fractions 52 intima media thickness IMT 52 severe exacerbations 52 HRQoL 52 mcg mL 52 arterial thromboembolic events 52 CIMZIA TM certolizumab pegol 52 FOLFOX4 52 saline placebo 52 FEV1 52 systemic embolism 52 CC genotype 52 ≤ 52 PSA nadir 52 covariate 52 leukocyte count 52 primary efficacy endpoint 52 IRLS 52 carotid intima media 52 coronary revascularization 52 endoscopic remission 52 Target Lesion Revascularization TLR 52 PCWP 52 fasting insulin 52 mmHg 52 alanine aminotransferase ALT 52 subtrochanteric 52 ipsilateral 52 Adverse events 52 #mg/kg [002] 52 response CCyR 52 Pred Forte 52 erythrocyte sedimentation rate 52 HAM D# 52 cytogenetic abnormalities 52 serologically active patients 52 BMS p = 52 rs# [003] 52 Psoriasis Area 52 Postoperatively 52 irbesartan 52 creatinine clearance 52 IQR = 52 spine BMD 52 randomized 52 symptom severity 52 PASI scores 52 FOLPI 51 biopsy Gleason 51 diastolic hypertension 51 apnea hypopnea index 51 Neuropsychiatric Inventory NPI 51 LS BMD 51 NMIBC 51 eptifibatide 51 Exclusion criteria 51 TAXUS Express Stent 51 CDAI score 51 ezetimibe simvastatin 51 Alzheimer Disease Assessment 51 pegylated interferon alfa 2b 51 bosentan 51 FDA defined valvulopathy 51 Score TOS 51 mL min 51 Kaplan Meier estimates 51 carotid IMT 51 mild renal impairment 51 CrCl 51 microg 51 logistic regression model 51 serum HBV DNA 51 mg dose 51 nicardipine 51 mg kg belimumab 51 clodronate 51 rho = 51 YMRS 51 plasma HCV RNA 51 multivariate adjusted 51 fractional anisotropy 51 mcg albinterferon alfa 2b 51 EDSS score 51 mean baseline A1C 51 logistic regression analysis 51 rheumatoid factor 51 cells mcL 51 seminal vesicle invasion 51 HBeAg positive patients 51 = [031] 51 glycated hemoglobin HbA1c 51 CsA 51 linaclotide treated 51 urate lowering therapy 51 NPH insulin 51 HDRS 51 Pain Intensity 51 aspartate aminotransferase AST 51 proteinuria 51 peripheral edema 51 locoregional recurrence 51 ug kg 51 randomization 51 HRCT 51 -#.# ± [001] 51 thromboembolic events 51 thromboembolic 51 HBeAg 51 symptom exacerbation 51 #.#mg/dL 51 mL kg 51 salmeterol fluticasone propionate 51 serum ALT 51 nonvertebral 51 estimated glomerular filtration 51 interquartile range IQR 51 Stent thrombosis 51 dyspareunia 51 EBRT 51 adjunctive ABILIFY 51 PANSS total 51 extensive metabolizers 51 Secondary efficacy endpoints 51 tiotropium 51 sirolimus stent 51 events AEs 51 serum retinol 51 Rating Scale BPRS 51 p = ns 51 Serum creatinine 51 Montgomery Åsberg Depression 51 serum phosphorus 51 cerebrovascular accident 51 genotypic resistance 51 doxorubicin docetaxel 51 SCr 51 = .# 51 Flu Cy 51 advanced adenomas 51 abciximab 51 mTSS 51 QoL 51 infarct size 51 β blockers 51 RGT arm 51 reoperation 51 eplerenone 51 detrusor overactivity 51 urine albumin 51 serum magnesium 51 recurrent VTE 51 concomitant medications 51 transaminase elevations 51 randomisation 51 fluticasone salmeterol 51 regression coefficient 51 LV dysfunction 51 clopidogrel 51 glimepiride 51 anemia hemoglobin 51 histological subtype 51 attain statistical significance 51 Visual Analog Scale 51 fasting plasma glucose FPG 51 ADAS Cog 51 Free Survival PFS 51 Score DAS# 51 Key secondary endpoints 51 ziprasidone 51 postprocedure 51 pericardial effusion 51 UPDRS 51 peginterferon alfa 2a 51 PCa 51 target lesion revascularization 51 echocardiographic parameters 51 dysuria 51 TT genotype 51 NIHSS score 50 androgen suppression 50 dysphoric 50 revascularizations 50 perioperative complications 50 rCBF 50 TURBT 50 neutrophil counts 50 placebo Hazard Ratio 50 plus dexamethasone 50 reintervention 50 mild renal insufficiency 50 DMARD 50 aspartate aminotransferase 50 Hb A1C 50 highest quintile 50 WOMAC 50 ADCS ADL 50 viral load 50 noncardiac 50 CVD mortality 50 prospectively stratified 50 6MWD 50 stent thromboses 50 lamivudine monotherapy 50 neutrophil count 50 min -1 50 MMSE 50 radiotherapy RT 50 ACR# response 50 radiographic progression 50 mIU ml 50 lymphocyte count 50 TDF FTC 50 treatment emergent adverse 50 Cmax 50 adefovir treated 50 titrated glipizide 50 mg 50 HAM D# scores 50 corrected QT interval 50 nmol 50 glycated hemoglobin levels 50 ischemia driven 50 pooled comparator 50 proximal DVT 50 microalbuminuria 50 inflammatory lesions 50 COPD exacerbation 50 left ventricular LV 50 Left Ventricular Ejection Fraction 50 Lumbar spine 50 Median survival 50 DES implantation 50 prospectively defined 50 arthralgia 50 ECOG PS 50 -#.# mmol L 50 mEq L 50 polyposis 50 AUCs 50 hypophosphatemia 50 #μg [002] 50 PREZISTA r arm 50 platelet reactivity 50 AUA Symptom Score 50 prostatic adenocarcinoma 50 poststroke 50 systolic dysfunction 50 mmHg systolic 50 tibiofemoral 50 GG genotype 50 probable stent thrombosis 50 FOLFOX 50 aortic regurgitation 50 multivariate analyzes 50 TIMP 1 50 phonophobia 50 T2 lesions 50 vasomotor 50 neurocognitive function 50 #mg BID [002] 50 leucopenia 50 racemic albuterol 50 Kaplan Meier survival 50 #OHD 50 seronegative 50 myocardial infarction 50 euthyroid 50 plus OBT 50 -#.# mm Hg 50 Q2W 50 oxycodone IR 50 fasting plasma glucose 50 psychiatric comorbidities 50 hypokalemia 50 lowest quintile 50 ATACAND 50 XIENCE V demonstrated 50 Partial Response 50 symptomatic VTE 50 NYHA functional class 50 mg Lucentis 50 serum PTH 50 mL 50 Elitek 50 glulisine 50 Thal Dex 50 #mg/dL [002] 50 pmol liter 50 placebo dexamethasone 50 rs# [004] 50 ug ml 50 albumin excretion rate 50 χ 50 IIIa inhibitor 50 HCV genotype 50 nonischemic 50 relapsers 50 noninferiority 50 SVR# 50 femoral shaft fracture 50 IELT 50 nonfasting triglyceride levels 50 myocardial infarction stroke 50 affective psychosis 50 radical prostatectomy RP 50 plus GP IIb 50 coinfected patients 50 coronary stenosis 50 uncoated stent 50 rizatriptan 50 thyroglobulin 50 adalimumab 50 serum estradiol 50 sUA 50 cystectomy 50 hsCRP levels 50 FluCAM arm 50 mL/min/#.# m2 50 GnRH agonist 50 MBq 50 IU ml 50 ALT elevation 50 histologically confirmed 50 depressive symptoms 50 logMAR 50 #.#/#.# mm Hg [003] 50 desvenlafaxine succinate 50 ng dl 50 Ishak fibrosis score 50 mRNA expression 50 Preoperatively 50 prednisone prednisolone plus 50 aminotransferases 50 NYHA class 50 plasma uric acid 50 cardiovascular hospitalizations 50 ANCOVA 50 serum urate levels 50 secondary efficacy endpoint 50 ADCS CGIC 50 oral allopurinol 50 Multivariate analysis 50 SUVmax 50 adefovir 50 plus glycoprotein IIb 50 baseline FEV 50 quetiapine risperidone 50 glycosylated hemoglobin 50 octreotide LAR 50 Y BOCS 50 glycoprotein IIb IIIa inhibitors 50 ribavirin RBV 50 #ug [001] 50 esomeprazole 50 lymph node metastasis 50 hemorrhagic complications 50 sinus rhythm 50 nM 50 postdischarge 49 docetaxel pretreated 49 Negative Syndrome 49 left ventricular dysfunction 49 nondiabetic 49 neurodevelopmental impairment 49 events TEAEs 49 non inferiority 49 Scale EDSS 49 TIMP 49 lymphopenia 49 incidence ≥ 49 elevated ALT 49 seroconversion 49 μg ml 49 mg tid 49 plus ribavirin 49 extracapsular extension 49 ml kg 49 antiretroviral naïve 49 mcg Albuferon 49 fractional shortening 49 chlorthalidone 49 exacerbations 49 achieve statistical significance 49 secondary efficacy endpoints 49 ertapenem 49 lacunar 49 statistical significance p = 49 Unified Parkinson Disease 49 revascularization procedures 49 cytogenetic response 49 systolic blood pressures 49 μg liter 49 APTIVUS r 49 HbA1C 49 ACR# ACR# 49 deep venous thromboses 49 inotropic agents 49 nodular partial response 49 lumbar spine bone 49 postoperative AF 49 affective psychoses 49 VT VF 49 Complication rates 49 Index CDAI score 49 hemoglobin A1c HbA1c 49 serum potassium 49 ecchymosis 49 LVSD 49 ACR# [002] 49 mU L 49 bivariate 49 SBMs 49 sociodemographic characteristics 49 IFN alfa 49 chemoradiation therapy 49 plasma leptin 49 overt nephropathy 49 splenic 49 lymphovascular invasion 49 carotid stenosis 49 pruritus 49 leuprorelin 49 lactate dehydrogenase 49 QTc 49 posttest 49 budesonide pMDI 49 undetectable HBV DNA 49 colorectal adenomas 49 pioglitazone 49 spontaneous bowel movements 49 mol L 49 QTc intervals 49 histologic 49 kg/m2 49 PSADT 49 CIMZIA TM 49 EDSS 49 postinjury 49 divalproex 49 statistically nonsignificant 49 fasting triglyceride levels 49 sirolimus eluting stent 49 Main Outcome Measures 49 neurologic progression 49 tapentadol ER 49 unfractionated heparin UFH 49 etanercept 49 detectable HCV RNA 49 renal insufficiency 49 suicidal ideation 49 insulin detemir 49 IRLS score 49 thromboembolism 49 tumor histology 49 infarcts 49 kg -1 49 noninferior 49 PREZISTA ritonavir 49 perioperatively 49 recurrent acute pancreatitis 49 repeat revascularization 49 postoperative complications 49 Kaplan Meier 49 beta blocker therapy 49 rehospitalization 49 severe hypoglycemia 49 β blocker 49 eGFR 49 RECIST criteria 49 progesterone receptor negative 49 baseline CD4 49 Score IPSS 49 solifenacin 49 Apgar scores 49 mM 49 partial remissions 49 interferon alfa 2a 49 Scale cognitive subscale 49 evaluable patients 49 mean baseline HbA1c 49 uM 49 FOLFIRI 49 sirolimus eluting stents 49 dyspnoea 49 plasma folate 49 acutely decompensated congestive heart 49 splenectomized 49 mmol kg 49 coronary artery stenosis 49 z = 49 systolic function 49 ventricular mass 49 Vancocin p = 49 Pearson correlation coefficient 49 Timed Walk 49 lateral radiograph 49 noncarriers 49 SSRI citalopram 49 ischemic lesions 49 virological failure 49 Global Impression 49 Zometa hazard 49 creatine kinase MB 49 intraoperative 49 symptomatic intracranial hemorrhage 49 homozygotes 49 invasive carcinomas 49 virological response 49 hematuria 49 HBeAg negative 49 anastomotic leak 49 lymphocytosis 49 hippocampal volume 49 baseline A1C 49 mg + GLY 49 parous women 49 prostate cancer CaP 49 GP IIb IIIa 49 Mean Symptom Complex 49 serum urate 49 headache nasopharyngitis 49 nocturnal awakenings 49 hyperintensity 49 subscores 49 pretest probability 49 locoregional disease 49 distensibility 49 gadolinium enhancing lesions 49 ALT normalization 49 moderate renal impairment 49 PegIFN RBV 49 ETDRS 49 Fasting plasma glucose 49 comorbid conditions 49 active comparator 49 BMI ≥ 49 esophageal carcinoma 49 isoproterenol 49 Cronbach alpha 49 Insulin sensitivity 49 beclomethasone dipropionate 49 prespecified secondary 49 non splenectomized 49 BPS IC 49 Erythropoietic therapies may 49 mg/m2 dose 49 urinary albumin 49 serum testosterone 49 DAS# CRP 49 logistic regression 49 daunorubicin 49 NSTEMI 49 enthesitis 48 nasal obstruction 48 serum creatinine 48 #.#ng/ml 48 neutropaenia 48 RYGB 48 fatigue asthenia 48 tipranavir ritonavir 48 laterality 48 dalteparin 48 biphasic insulin aspart 48 nonvertebral fractures 48 lumen diameter 48 IM progesterone 48 depressive symptomatology 48 troponin T 48 advanced neoplasia 48 CIBIC plus 48 splenectomized patients 48 IBDQ 48 mg qd 48 CSBMs 48 + PH# 48 Kaplan Meier curves 48 stage IIIb IV 48 nondepressed 48 lipid parameters 48 adenotonsillectomy 48 titrated glipizide plus 48 symptomatic AF 48 confirmed CCyR 48 #q# deletion syndrome 48 refractory NSCLC 48 primary patency 48 thrombocytopenia 48 immunostaining 48 cGy 48 mineral density 48 SGPT 48 postoperative mortality 48 cardioembolic 48 olanzapine 48 URTI 48 flutamide 48 elevated IOP 48 mL sec 48 retinal thickness 48 amoxicillin clavulanate 48 FEV ^ sub 48 cerebral oxygenation 48 odds ratios ORs 48 mg Androxal 48 cardiovascular mortality 48 Gy 48 venlafaxine XR 48 adriamycin 48 asthma exacerbation 48 apnea hypopnea 48 periprocedural MI 48 FluCAM 48 mg BID dose 48 SBM frequency 48 tumor progression TTP 48 metformin IR 48 macroalbuminuria 48 segment binary restenosis 48 intraclass correlation coefficient 48 renal dysfunction 48 affective disorders 48 cirrhotic 48 cisplatin vinorelbine 48 preoperative chemotherapy 48 multivariable Cox 48 interobserver reliability 48 UACR 48 nondiabetics 48 nadolol 48 enoxaparin 48 ± SEM 48 BEACOPP 48 nasopharyngitis headache 48 seropositivity 48 rs# [002] 48 hours postdose 48 atherosclerotic renal artery stenosis 48 fosamprenavir 48 diuretic chlorthalidone 48 conduction velocity 48 graft occlusion 48 femoral neck fracture 48 gastric pH 48 sensory neuropathy 48 revascularization 48 clinically meaningful improvements